These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 23647714

  • 1. Switching from biphasic human insulin to biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN subgroup of the A₁chieve study.
    Hussein Z, Lim-Abrahan MA, Jain AB, Goh SY, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S24-9. PubMed ID: 23647714
    [Abstract] [Full Text] [Related]

  • 2. Safety and effectiveness of biphasic insulin aspart 30 in a Bangladeshi subgroup of type 2 diabetic patients switched from biphasic human insulin 30: a sub-analysis of the A₁chieve study.
    Latif ZA, Pathan MF, Siddiqui MN, Sobhan MJ, Rahman MM, Ashrafuzzaman SM.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S30-4. PubMed ID: 23647716
    [Abstract] [Full Text] [Related]

  • 3. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Filipino cohort of the A₁chieve study.
    Lim-Abrahan MA, Yu-Gan S, Jain AB, Sobrepena LM, Racho VA.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S35-40. PubMed ID: 23647717
    [Abstract] [Full Text] [Related]

  • 4. Clinical safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes patients switched from biphasic human insulin 30: results from the Indonesian cohort of the A₁chieve study.
    Soewondo P, Lindarto D, Wibisono S, Renaldi O, Dalem-Pemayun TG.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S41-6. PubMed ID: 23647718
    [Abstract] [Full Text] [Related]

  • 5. Safety and effectiveness of biphasic insulin aspart 30 in type 2 diabetes: results from the ASEAN cohort of the A₁chieve study.
    Lim-Abrahan MA, Jain AB, Bebakar WM, Seah D, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S3-9. PubMed ID: 23647715
    [Abstract] [Full Text] [Related]

  • 6. Safety and effectiveness of insulin aspart in type 2 diabetic patients: results from the ASEAN cohort of the A₁chieve study.
    Bebakar WM, Lim-Abrahan MA, Jain AB, Seah D, Soewondo P.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S17-23. PubMed ID: 23647713
    [Abstract] [Full Text] [Related]

  • 7. Clinical experience with BIAsp 30: results from the Indonesian cohort of the international A₁chieve study.
    Soewondo P, Pramono RB, Langi YA, Soetedjo NN, Kshanti IA.
    Diabetes Res Clin Pract; 2013 Apr; 100 Suppl 1():S54-9. PubMed ID: 23647720
    [Abstract] [Full Text] [Related]

  • 8. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: a 26-week, randomised, treat-to-target trial.
    Kaneko S, Chow F, Choi DS, Taneda S, Hirao K, Park Y, Andersen TH, Gall MA, Christiansen JS, BOOST: Intensify All Trial Investigators.
    Diabetes Res Clin Pract; 2015 Jan; 107(1):139-47. PubMed ID: 25498130
    [Abstract] [Full Text] [Related]

  • 9. Switching from biphasic human insulin 30 to biphasic insulin aspart 30 in type 2 diabetes is associated with improved glycaemic control and a positive safety profile: results from the A₁chieve study.
    El Naggar NK, Soewondo P, Khamseh ME, Chen JW, Haddad J.
    Diabetes Res Clin Pract; 2012 Dec; 98(3):408-13. PubMed ID: 23217267
    [Abstract] [Full Text] [Related]

  • 10. Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.
    Belhadj M, Dahaoui A, Jamoussi H, Farouqi A.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S4-14. PubMed ID: 23958571
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of biphasic insulin aspart 30 in type 2 diabetes patients switched from either biphasic or basal human insulin: results from the Gulf cohort of the A1 chieve study.
    Almansari A, Khader S, Kharawagh A, AbdelFattah W, Badawy T.
    Int J Clin Pract; 2014 Jul; 68(7):850-6. PubMed ID: 24548757
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W, Ma J, Hong T, Liu M, Miao H, Peng Y, Wang C, Xu X, Yang T, Nielsen AM, Pan L, Liu W, Zhao W.
    Diabetes Obes Metab; 2019 Jul; 21(7):1652-1660. PubMed ID: 30869183
    [Abstract] [Full Text] [Related]

  • 13. Safety and effectiveness of biphasic insulin aspart 30 in people with type 2 diabetes switching from basal-bolus insulin regimens in the A1chieve study.
    Dieuzeide G, Chuang LM, Almaghamsi A, Zilov A, Chen JW, Lavalle-González FJ.
    Prim Care Diabetes; 2014 Jul; 8(2):111-7. PubMed ID: 23953707
    [Abstract] [Full Text] [Related]

  • 14. Predictors of achieving HbA(1c) <7% and no hypoglycaemia 6 months after initiation of biphasic insulin aspart 30 in patients with type 2 diabetes in the IMPROVE study.
    Valensi P, Shaban J, Benroubi M, Kawamori R, Borzì V, Shah S, Wenying Y, Prusty V, Hansen JB, Gumprecht J, IMPROVE Study Expert Panel.
    Curr Med Res Opin; 2013 Jun; 29(6):601-9. PubMed ID: 23488447
    [Abstract] [Full Text] [Related]

  • 15. Switch from biphasic human insulin 30 to biphasic insulin aspart 30 in Pakistani subjects.
    Hassan MI, Aamir AH, Miyan Z, Siddiqui LA, Mahmood S, Vohra EA.
    J Pak Med Assoc; 2013 Oct; 63(10):1290-4. PubMed ID: 24392563
    [Abstract] [Full Text] [Related]

  • 16. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S, Hyllested-Winge J, Gall MA, Kaneko S, Hirao K.
    J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
    [Abstract] [Full Text] [Related]

  • 17. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G.
    Clin Ther; 2005 Mar; 27 Suppl B():S57-74. PubMed ID: 16519038
    [Abstract] [Full Text] [Related]

  • 18. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S, Sothiratnam R, Sari R, Andersen H, Hiort LC, Rao P.
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [Abstract] [Full Text] [Related]

  • 19. Safety and effectiveness of insulin analogues in type 2 diabetic patients from Algeria: a sub-analysis of the A₁chieve study.
    Malek R, Arbouche Z, Dahaoui A, Bachaoui M.
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S15-26. PubMed ID: 23958568
    [Abstract] [Full Text] [Related]

  • 20. Twice-daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin-naïve adults with Type 2 diabetes.
    Franek E, Haluzík M, Canecki Varžić S, Sargin M, Macura S, Zacho J, Christiansen JS.
    Diabet Med; 2016 Apr; 33(4):497-505. PubMed ID: 26435365
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.